Vinorelbine and cisplatin combined with endostatin as the first-line therapy for metastatic pancreatic cancer
Objective Systemic chemotherapy for metastatic pancreatic cancer is still a difficult problem in clinical practice. The standard chemotherapy of pancreatic cancer has been gemcitabine, but the response rate is low. Therefore, it is in urgent need to explore an effective clinical therapy for this cancer. This paper, a case report, is aimed at discussing the effectiveness of vinorelbine and cisplatin combined with endostatin as the first-line therapy for metastatic pancreatic cancer. Methods A 52-year-old female patient was diagnosed with pancreas cancer with liver metastasis at the time of the first visit to our hospital. Systemic chemotherapy with vinorelbine and cisplatin combined with endostatin was conducted. Results Liver metastases almost disappeared after the first cycle of chemotherapy. The primary tumor decreased by one third in size after four cycles and disappeared after the sixth cycle according to the CT scan evaluation. Conclusion Vinorelbine and cisplatin combined with endostatin can be a promising regimen for metastatic pancreatic cancer.
作 者： Dong-Min Chang Can Zhou Yong Zhang De-Qiang Chen Gang Ma Feng Cao 作者单位： Department of Surgical Oncology, the First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710061, China 刊 名： 西安交通大学学报（英文版） 英文刊名： ACADEMIC JOURNAL OF XI'AN JIAOTONG UNIVERSITY(ENGLISH EDITION) 年，卷(期)： 2010 22(1) 分类号： U4 关键词： pancreatic cancer chemotherapy endostatin